ResearchMoz

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

GBI Research
Published Date » 2012-01-01
No. Of Pages » 165
   
 GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.  
   
 Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 ENT Disorders Market - Introduction
2.1 GBI Research Report Guidance

3 ENT Disorders Market - Market Overview
3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics
3.2 Gross Maldistribution
3.3 ENT Disorders Marked By Antibiotic Overuse
3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations
3.4.1 Ketolides - A New Class of Antibacterials
3.5 Revenue Forecasts
3.6 Annual Cost of Therapy
3.7 Treatment Usage Patterns
3.7.1 Diseased Population
3.7.2 Treatment Seeking Population
3.7.3 Diagnosed Population
3.7.4 Prescription Population
3.8 Drivers and Restraints of the ENT Disorders Market
3.8.1 ENT Disorders Market Drivers
3.8.2 ENT Disorders Market Restraints

4 ENT Disorders Market - Therapeutic Landscape
4.1 Tonsillitis Market
4.1.1 Introduction
4.1.2 Revenue Forecasts
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Flow Algorithm
4.1.5 Treatment Usage Patterns
4.1.6 Profiles of Key Drugs in the Tonsillitis Market
4.1.7 Geographical Segmentation
4.2 Sinusitis Market
4.2.1 Introduction
4.2.2 Revenue Forecasts
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Flow Algorithm
4.2.5 Treatment Usage Patterns
4.2.6 Profiles of Key Drugs in the Sinusitis Market
4.2.7 Geographical Segmentation
4.3 Rhinitis Market
4.3.1 Introduction
4.3.2 Revenue Forecasts
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Flow Algorithm
4.3.5 Treatment Usage Patterns
4.3.6 Profiles of Key Drugs in the Rhinitis Market
4.3.7 Geographical Segmentation
4.4 Otitis Media Market
4.4.1 Introduction
4.4.2 Revenue Forecasts
4.4.3 Annual Cost of Therapy
4.4.4 Treatment Flow Algorithm
4.4.5 Treatment Usage Patterns
4.4.6 Profiles of Key Drugs in the Otitis Media Market
4.4.7 Geographical Segmentation
4.5 Tracheobronchitis Market
4.5.1 Introduction
4.5.2 Revenue Forecasts
4.5.3 Annual Cost of Therapy
4.5.4 Treatment Flow Algorithm
4.5.5 Treatment Usage Patterns
4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market
4.5.7 Geographical Segmentation

5 ENT Disorders Market - Geographical Landscape
5.1 The US
5.1.1 Revenue Forecasts
5.1.2 Annual Cost of Therapy
5.1.3 Treatment Usage Patterns
5.2 Top Five Countries in Europe
5.2.1 Revenue Forecasts
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Japan
5.3.1 Revenue Forecasts
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns

6 ENT Disorders Market - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Tonsillitis
6.1.2 Research and Development Pipeline - Sinusitis
6.1.3 Research and Development Pipeline - Rhinitis
6.1.4 Research and Development Pipeline - Otitis Media

7 ENT Disorders Market - Competitive Landscape
7.1 Competitive Profiling
7.1.1 Abbott Laboratories
7.1.2 Bayer AG
7.1.3 GlaxoSmithKline
7.1.4 Johnson & Johnson (J&J)
7.1.5 Merck & Co
7.1.6 Pfizer
7.1.7 Novartis AG
7.1.8 F. Hoffmann-La Roche Ltd.
7.1.9 Sanofi

8 ENT Disorders Market - Strategic Consolidations
8.1 Overview
8.2 ENT Disorders Market M&A Deals
8.2.1 M&A Deals by Geography
8.2.2 Deals by Type
8.2.3 Major M&A Deals
8.3 R&D Licensing Agreements
8.3.1 Deals by Indication
8.3.2 Deals by Geography
8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin

9 ENT Disorders Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Geographical Landscape
9.3.5 Pipeline Analysis
9.3.6 Competitive Landscape
9.3.7 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

List of Tables


Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002-2010
Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 6: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2010-2017
Table 7: ENT Disorders Market, Global, Tonsillitis Revenue ($m), 2002-2010
Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2010-2017
Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2010
Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2010-2017
Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2010
Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2010-2017
Table 13: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2010
Table 14: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2010-2017
Table 15: ENT Disorders Market, Global, Sinusitis Revenue ($bn), 2002-2010
Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2010-2017
Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2010
Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2010-2017
Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2010
Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2010-2017
Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2002-2010
Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2010-2017
Table 23: ENT Disorders Market, Global, Rhinitis Revenue ($bn), 2002-2010
Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2010-2017
Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2010
Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2010-2017
Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2010
Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2010-2017
Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2002-2010
Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2010-2017
Table 31: ENT Disorders Market, Global, Otitis Media Revenue ($m), 2002-2010
Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2010-2017
Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2010
Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2010-2017
Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2010
Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2010-2017
Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2010
Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2010-2017
Table 39: ENT Disorders Market, Global, Tracheobronchitis Revenue ($m), 2002-2010
Table 40: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2010-2017
Table 41: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2010
Table 42: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2010-2017
Table 43: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2010
Table 44: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2010-2017
Table 45: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2010
Table 46: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2010-2017
Table 47: ENT Disorders Market, Global, Revenue by Geography ($bn), 2002-2010
Table 48: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017
Table 49: ENT Disorders Market, The US, Revenue ($bn), 2002-2010
Table 50: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2010-2017
Table 51: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2010
Table 52: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2010-2017
Table 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2010
Table 54: ENT Disorders Market, The US, Treatment Usage Patterns (million), 2010-2017
Table 55: ENT Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010
Table 56: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017
Table 57: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 58: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 59: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010
Table 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017
Table 61: ENT Disorders Market, Japan, Revenues ($m), 2002-2010
Table 62: ENT Disorders Market, Japan, Revenues ($m), 2010-2017
Table 63: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2010
Table 64: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2010-2017
Table 65: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2010
Table 66: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2010-2017
Table 67: ENT Disorders Market, Global, Tonsillitis Phase III Clinical Pipeline, 2011
Table 68: ENT Disorders Market, Global, Sinusitis Phase III Clinical Pipeline, 2011
Table 69: ENT Disorders Market, Global, Rhinitis Phase III Clinical Pipeline, 2011
Table 70: ENT Disorders Market, Global, Rhinitis Phase II Clinical Pipeline, 2011
Table 71: ENT Disorders Market, Global, Rhinitis Phase I Clinical Pipeline, 2011
Table 72: ENT Disorders Market, Global, Rhinitis Pre-clinical Pipeline, 2011
Table 73: ENT Disorders Market, Global, Otitis Media, Regulatory Filing and Phase III Clinical Pipeline, 2011

List of Figures


Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 3: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002-2017
Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002-2017
Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002-2017
Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002-2017
Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2011
Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002-2017
Figure 10: ENT Disorders Market, Global, Tonsillitis Therapeutics Market, Branded and Generic Share, (%), 2010
Figure 11: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2017
Figure 12: ENT Disorders Market, Global, Tonsillitis, Treatment Flow Algorithm
Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2017
Figure 14: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002-2017
Figure 15: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002-2017
Figure 16: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002-2017
Figure 17: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002-2017
Figure 18: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, (%), 2010 and 2017
Figure 19: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2017
Figure 20: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002-2017
Figure 21: ENT Disorders Market, Global, Sinusitis Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 22: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2017
Figure 23: ENT Disorders Market, Global, Sinusitis, Treatment Flow Algorithm
Figure 24: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2017
Figure 25: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002-2017
Figure 26: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002-2017
Figure 27: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002-2017
Figure 28: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002-2017
Figure 29: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2010 and 2017
Figure 30: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002-2017
Figure 31: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002-2017
Figure 32: ENT Disorders Market, Global Rhinitis, Branded and Generic Share, (%), 2010 and 2017
Figure 33: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2017
Figure 34: ENT Disorders Market, Global, Rhinitis, Treatment Flow Algorithm
Figure 35: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2017
Figure 36: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002-2017
Figure 37: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002-2017
Figure 38: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002-2017
Figure 39: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002-2017
Figure 40: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2010 and 2017
Figure 41: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002-2017
Figure 42: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002-2017
Figure 43: ENT Disorders Market, Global, Otitis Media Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 44: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2017
Figure 45: ENT Disorders Market, Global, Otitis Media, Treatment Flow Algorithm
Figure 46: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2017
Figure 47: ENT Disorders Market, Global, Otitis Media, Causes (%), 2011
Figure 48: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002-2017
Figure 49: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002-2017
Figure 50: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002-2017
Figure 51: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002-2017
Figure 52: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, (%), 2010 and 2017
Figure 53: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2017
Figure 54: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2002-2017
Figure 55: ENT Disorders Market , Global, Tracheobronchitis Therapeutics Market, Branded and Generic Share (%), 2010 and 2017
Figure 56: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2017
Figure 57: ENT Disorders Market, Global, Tracheobronchitis, Treatment Flow Algorithm
Figure 58: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2017
Figure 59: ENT Disorders Market, Global, Tracheobronchitis Diseased Population (million), 2002-2017
Figure 60:ENT Disorders Market, Global, Tracheobronchitis Treatment Seeking Population (million), 2002-2017
Figure 61: ENT Disorders Market, Global, Tracheobronchitis Diagnosed Population (million), 2002-2017
Figure 62: ENT Disorders Market, Global, Tracheobronchitis Prescription Population (million), 2002-2017
Figure 63: ENT Disorders Market, Global, Tracheobronchitis Market Segmentation by Geography, 2010 and 2017
Figure 64: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2017
Figure 65: ENT Disorders Market, Global, Market Share by Geography, (%), 2010 and 2017
Figure 66: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017
Figure 67: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002-2017
Figure 68: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2017
Figure 69: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2017
Figure 70: ENT Disorders Market, The US, Diseased Population (million), 2002-2017
Figure 71: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002-2017
Figure 72: ENT Disorders Market, The US, Diagnosed Population (million), 2002-2017
Figure 73: ENT Disorders Market, The US, Prescription Population (million), 2002-2017
Figure 74: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017
Figure 75: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 76: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017
Figure 77: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017
Figure 78: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017
Figure 79: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017
Figure 80: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017
Figure 81: ENT Disorders Market, Japan, Revenues ($m), 2002-2017
Figure 82: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2017
Figure 83: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2017
Figure 84: ENT Disorders Market, Japan, Diseased Population (million), 2002-2017
Figure 85: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002-2017
Figure 86: ENT Disorders Market, Japan, Diagnosis Population (million), 2002-2017
Figure 87: ENT Disorders Market, Japan, Prescription Population (million), 2002-2017
Figure 88: ENT Disorders Market, Global, R&D Pipeline by Indication (%), 2011
Figure 89: ENT Disorders Market, Global, R&D Pipeline by Phase (%), 2011
Figure 90: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), 2011
Figure 91: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), 2011
Figure 92: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), 2011
Figure 93: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2011
Figure 94: ENT Disorders Market, Global, SWOT - Bayer AG, 2011
Figure 95: ENT Disorders Market, Global, SWOT - GSK, 2011
Figure 96: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2011
Figure 97: ENT Disorders Market, Global, SWOT - Merck, 2011
Figure 98: ENT Disorders Market, Global, SWOT - Pfizer, 2011
Figure 99: ENT Disorders Market, Global, SWOT - Novartis, 2011
Figure 100: ENT Disorders Market, Global, SWOT - Roche, 2011
Figure 101: ENT Disorders Market, Global, SWOT- Sanofi, 2011
Figure 102: ENT Disorders Market, Global, M&A Deals by Indication (%), 2004-2011
Figure 103: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004-2011
Figure 104: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004-2011
Figure 105: ENT Disorders Market, Global, Licensing Deals by Indication (%), 2004-2011
Figure 106: ENT Disorders Market, Global, Licensing Deals By Geography, (%), 2004-2011
Figure 107: GBI Research Market Forecasting Model

Upcoming Reports:

Real Time Location System (RTLS) Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Real time location systems allow a user to identify and track the location of objects in real time by attaching a simple tag or badge to the object. The user can receive the signal from this badge to track the exact position of the object. RTLS integrates with a system that provides passive or active information of location. Real time systems help companies to arrange their assets effectively. This machinery is specially used in various warehouses or logistics companies to track the exact position of automobiles. In 2011, the RTLS market was reported to be about USD 256...
Milk Powder Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Milk powder is a perfect solution to those who lack immediate access to adequate refrigeration methods and dairy products. Milk powder results from extracting water content out of milk. The major purpose of converting milk into milk powder is because it can be preserved and has a longer shelf life. Powdered milk includes items such as dry whole milk, dry butter milk, dry whey products, dry dairy blends, and nonfat dry milk. Milk powder has various applications in confectionaries, bakeries, infant formulae, nutritional foods etc.  China, U.S. and France are the...
RSV Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting in serious illness. Common symptoms of RSV infection include, cold, cough, headache and weakness. Human...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...